Related Experiment Videos

Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis

Urs B Schaad1, Patricia Kellerhals, Martin Altwegg

  • 1University Children's Hospital of Basel, Zurich, Switzerland. urs-b.schaad@unibas.ch

Insights

A 3-day azithromycin course for group A streptococcal (GAS) pharyngitis showed similar clinical success to 10-day penicillin V but had significantly lower bacteriologic eradication rates in children.

Area of Science:

  • Pediatric Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Acute group A streptococcal (GAS) pharyngitis is a common childhood infection.
  • Penicillin V has been the standard treatment, but concerns about adherence and resistance exist.
  • Azithromycin offers a shorter treatment course, potentially improving compliance.

Purpose of the Study:

  • To compare the clinical and bacteriologic efficacy of a 3-day azithromycin regimen versus a 10-day penicillin V regimen for treating acute GAS pharyngitis in children.
  • To investigate the impact of viral infections and GAS carriage on treatment outcomes.

Main Methods:

  • A multicenter, randomized, open-label study compared 10 mg/kg/day azithromycin for 3 days with 100,000 IU/kg/day penicillin V for 10 days in children with GAS pharyngitis.
  • Clinical and bacteriologic outcomes, as well as tolerability, were assessed.
  • Patients were monitored for symptom recurrence for 6 months.

Main Results:

  • Clinical cure/improvement rates were similar for both azithromycin (95%) and penicillin V (97%) at Day 14, and (94% vs. 95%) at Day 28.
  • Bacteriologic eradication was significantly lower with azithromycin (38% at Day 14, 31% at Day 28) compared to penicillin V (81% at Day 14, 68% at Day 28).
  • Both treatments were well-tolerated, with no increase in GAS-related sequelae.

Conclusions:

  • A 3-day azithromycin regimen achieves similar clinical efficacy to a 10-day penicillin V regimen for GAS pharyngitis in children.
  • However, azithromycin is associated with significantly lower bacteriologic eradication rates.
  • The choice of antibiotic should consider both clinical outcomes and bacteriologic eradication potential.
Abstract

Related Concept Videos